Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 5074 in Mild Cognitive Impairment (CT05)
NCT01723670Phase 2Withdrawn
- Sponsor
- CereSpir
- Start
- Dec 2012
- Primary completion
- Mar 2016
01
Overview
A Phase 2 trial of Itanapraced in Mild Cognitive Impairment (MCI), sponsored by CereSpir. Planned start Dec 2012; status: withdrawn.
02
Drugs
Itanapraced
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01723670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01723670.